Join to View Full Profile
77 Avenue Louis PasteurBoston, MA 02115
Phone+1 617-525-4803
Dr. Maron is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's HospitalFellowship, Cardiovascular Disease, 2008 - 2011
Boston University Medical CenterResidency, Internal Medicine, 2003 - 2005
The Warren Alpert Medical School of Brown UniversityClass of 2003
Certifications & Licensure
MA State Medical License 2006 - 2025
MD State Medical License 2023 - 2025
NH State Medical License 2024 - 2024
American Board of Internal Medicine Cardiovascular Disease
Clinical Trials
- The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study Start of enrollment: 2015 Sep 01
- Pulmonary Hemodynamics During Exercise - Research Network Start of enrollment: 2018 Dec 01
Roles: Contact
Publications & Presentations
PubMed
- Right heart catheterization in heart failure: indications, interpretation, and pitfalls.Katarina Zeder, Susanna Mak, Nazzareno Galie, Stephan Rosenkranz, Bradley A Maron
European Heart Journal. 2025-06-16 - Comprehensive analysis of multi-omics single-cell data using the single-cell analyst.Lu Pan, Bufu Tang, Xuan Zhang, Paolo Parini, Roman Tremmel
Imeta. 2025-06-01 - Longitudinal Pulmonary Arterial Pressure Trajectories Inform Clinical Outcome in Kidney Transplantation Patients.Katarina Zeder, Suman Kundu, Edward D Siew, Jeffrey S Annis, Laurel Y Lee
Chest. 2025-05-29
Lectures
- A Panoply of Perspectives on Pulmonary Hypertension: Patients Practitioners and Political Advocates2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
- Co-Moderator: Plain Spoken Perspectives on Pulmonary Hypertension2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
- Addition of Spironolactone to Ambrisentan May Be a Novel Treatment Strategy to Improve Outcome in Patients With PAH2013 International Conference, Philadelphia, Pennsylvania, USA
- Join now to see all
Press Mentions
In High‑Risk PAH, Sotatercept Shows “Transformative” Clinical BenefitJune 10th, 2025- Print Publication of ZENITH and SOUL Trials Spark Continued DialogueJune 5th, 2025
- HMN 2025: How New Pulmonary Arterial Hypertension Therapy Provides Hope for Sufferers in Superior Stage of IllnessMay 31st, 2025
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
